Ibogaine has been used for centuries by members of the Bwiti religion in western equatorial Africa as a religious sacrament, medicine and hunting aid. Since the discovery of the ability of ibogaine to interrupt addiction and withdrawal symptoms by Howard Lotsof it has also become of interest to the West. The complex pharmacology of ibogaine, in addition to its natural origin has caused it to be a substance that is of little interest to the pharmaceutical industry. However, over the years ibogaine has proven to be at least reasonably effective in treating different substance addictions in animal models. In the few clinical trials that were performed ibogaine showed promising results. Setbacks in the development of the drug have been its neurotoxic effects in rats and a number of deaths that were related to its use. In recent years little has been published regarding ibogaine research. In the meanwhile ibogaine use appears to be increasing in non-clinical settings and private clinics all over the world, the uncontrolled experiment continues. Should further research into ibogaine be pursued?
Ruud Litjens – Ibogaine in the Treatment of Substance Dependence
Join ICPR 2022 Online!
ICPR features world-leading experts from many academic disciplines, including psychiatry, psychology, neuroscience, anthropology, ethnobotany, and philosophy who come together to give a scientific conference for academics, therapists, researchers, clinicians, policymakers, and members of the public. Get your ICPR 2022 livestream ticket today and use the code OPENLIVE30 at checkout for a €30 discount.
INTERESTED IN PSYCHEDELIC RESEARCH AND THERAPIES?
Subscribe to our new OPEN-Minded newsletter to stay in the loop, hear about our events, and become a part of a community dedicated to advancing psychedelics.
By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.